$100m Injection Ushers CeQur’s Insulin Patch Towards 2016 US Approval
This article was originally published in Clinica
Executive Summary
CeQur SA is nearing the final hurdle in a seven-year journey to commercialize its PaQ three-day insulin infusion device.